Eisai Facility FDA-483 Out
FDA has just released the form FDA-483 issued following a 10/23-10/27/2023 inspection at the Eisai drug manufacturing facility in Gifu, Japan. The two observations were:
- failure to maintain in writing and fully follow the responsibilities and procedures applicable to the quality control unit; and
- failure to store drug products under appropriate conditions of humidity so that their identity, strength, quality, and purity are not affected.